CARCINOMA

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This phase 2 study tests whether adding savolitinib to osimertinib can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to osimertinib alone. About 367 participants will receive the drug…

This phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to…

This study tests whether adding savolitinib to osimertinib works better than chemotherapy for people with a certain type of advanced lung cancer (EGFR-mutated, MET-positive) that has stopped responding to osimertinib. About 345 adults will be randomly assigned to receive either t…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…

This early-phase trial tests a combination of three drugs for people whose appendix or colon cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). After surgery to remove visible tumors, patients receive chemotherapy directly into the abdomen (oxaliplatin) p…

This study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…

This study tests a computer program that analyzes colonoscopy images to help doctors decide if a growth (polyp) is an adenoma (pre-cancerous) or not. The software gives a probability score for each lesion. The trial involves 1,178 adults and compares the software's results to lab…

This study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…

This study compares two treatments for early-stage throat cancer: robotic surgery (TORS) or radiation therapy (IMRT). It looks at which one leads to better swallowing function and overall quality of life. About 138 adults with HPV-related throat cancer are taking part. The goal i…

This study collects blood and urine samples from 1,000 adults receiving radiation therapy for cancer. Researchers want to learn how radiation affects gene activity in white blood cells, damages red blood cells, and changes hormone levels. No new treatment is being tested—this is …